<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23484">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801071</url>
  </required_header>
  <id_info>
    <org_study_id>PPS</org_study_id>
    <nct_id>NCT02801071</nct_id>
  </id_info>
  <brief_title>L-Citrulline in Patients With Post-Polio Syndrome</brief_title>
  <official_title>&quot;Treatment With L-citrulline in Patients With Post-polio Syndrome - a Randomized Double Blind Placebo Controlled Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dirk Fischer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to show that the intake of L-citrulline improves muscle function
      in patients with Post-Polio Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomized, double-blind, placebo controlled study. The study
      medication consists of L-citrulline, respectively placebo given orally; 5 g L-citrulline or
      placebo will be given three times daily. The duration of the study is 48 weeks and
      comprehends one screening and four study visits.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of 6 Minute Walking Distance(6MWD)</measure>
    <time_frame>Baseline to week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of MFM total score</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quantitative muscle MRI (IDEAL-CPMG with Tâ‚‚ and lipid quantitation and dynamic 31P-MR spectroscopy)</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum concentrations for markers of muscle necrosis</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum concentrations for markers of oxidative stress</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum concentrations for markers of nitrosative stress</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum concentrations for markers of mitochondrial related genes</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Post-Polio Syndrome</condition>
  <arm_group>
    <arm_group_label>L-citrulline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 g L-citrulline p.o. per day (3x 5g) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>L-citrulline Placebo 3 times daily p.o. for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15g L-citrulline daily p.o.</intervention_name>
    <arm_group_label>L-citrulline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior paralytic poliomyelitis with evidence of motor neuron loss

          -  A period of partial or complete functional recovery after acute paralytic
             Poliomyelitis

          -  Slowly progressive and persistent new muscle weakness or decreased endurance, with or
             without generalized fatigue, muscle atrophy, or muscle and joint pain. Symptoms that
             persist for at least a year

          -  Exclusion of other neuromuscular, medical and skeletal abnormalities as causes of
             symptoms

          -  Patients older than 18 years at time of Screening

          -  ambulant

          -  ability to walk 150m in the 6 min. Walking distance (6MWD)

          -  females of childbearing potential willing to use contraceptive during the study

        Exclusion Criteria:

          -  Previous (3 months or less) or concomitant participation in any other therapeutic
             trial

          -  Use of L-citrulline or L-arginine within the last 3 months

          -  Known individual hypersensitivity to L-citrulline

          -  Known or suspected malignancy

          -  Other chronic disease or clinical relevant limitation of renal, liver, heart function
             according to discretion of investigator

          -  Pregnant or breast-feeding women

          -  Severe renal failure (calculated GFR &lt; 30 ml/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Fischer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Basel, Children's Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>June 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Dirk Fischer</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Post-Polio Syndrome</keyword>
  <keyword>PPS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Postpoliomyelitis Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
